Background: Recent literature suggests that children who are vitamin D deficient are uniquely susceptible to the effects of traffic-related air pollution (TRAP) exposure. This is highly significant because large segments of the population reside in zones of high TRAP exposure. Objective: We sought to determine whether vitamin D supplementation mitigates the effect of TRAP exposure on asthma development, asthma exacerbation, and/or airway inflammation and to determine the timing of vitamin D supplementation that confers maximal health benefit. Methods: Using established mouse models of asthma, we examined the effect of prenatal and postnatal vitamin D
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Background: Recent literature suggests that children who are vitamin D deficient are uniquely susceptible to the effects of traffic-related air pollution (TRAP) exposure. This is highly significant because large segments of the population reside in zones of high TRAP exposure. Objective: We sought to determine whether vitamin D supplementation mitigates the effect of TRAP exposure on asthma development, asthma exacerbation, and/or airway inflammation and to determine the timing of vitamin D supplementation that confers maximal health benefit. Methods: Using established mouse models of asthma, we examined the effect of prenatal and postnatal vitamin D supplementation on asthma development, as well as the utility of vitamin D as a treatment for established asthma in the context of diesel exhaust particle (DEP) exposure. Results: DEP and allergen coexposure resulted in increased airway hyperresponsiveness (AHR) and accumulation of pathogenic T H 2/T H 17 cells in the lungs of vitamin D-deficient mice compared with control mice. Prenatal and postnatal vitamin D supplementation significantly attenuated the development of AHR and decreased pulmonary accumulation of T H 2/T H 17 cells after coexposure to TRAP and allergen but not to allergen alone. Restoration of normal vitamin D status had no effect on AHR once asthma was already established. factor to the increase in asthma seen in the past 2 decades. 3 As such, numerous trials have been conducted to examine the efficacy of vitamin D supplementation on preventing or attenuating asthma symptoms, and the results have been mixed. A recent review concluded that ''limited information is available addressing primary prevention of allergic diseases after vitamin D supplementation, and its potential impact remains uncertain.'' 4 Part of the reason for this is the lack of understanding of who would benefit most from vitamin D supplementation and when supplementation would be most effective.
Traffic-related air pollution (TRAP) is a significant contributor to particulate matter exposure levels in children. 5 A recent comprehensive and systematic review of worldwide traffic emissions and health science by a special panel convened by the Health Effects Institute found sufficient evidence that exposure to TRAP causes asthma exacerbation in children and likely promotes asthma development in early life. 6 Diesel exhaust particles (DEPs), the predominant particulate matter component of TRAP, have the unique ability to reach the small airways, including the alveolar gas exchange region, further exacerbating asthma symptoms. 7, 8 DEPs are composed of elemental carbon cores with large surface areas capable of binding organic polycyclic aromatic hydrocarbons, transition metals, and airborne allergens, which have the potential to induce reactive oxygen species and inflammation. 9, 10 A recent study revealed that children who were both vitamin D deficient and living near a major roadway were 5 times more likely to experience asthma exacerbations in comparison with children who were vitamin D sufficient and living in the same regions of high TRAP exposure. 11 These data suggest that vitamin D deficiency can render children uniquely susceptible to the adverse effects of TRAP. This is highly significant because 45% of the US population, including children, reside in zones of high exposure, 12 and TRAP exposure leads to more severe allergic asthma characterized by T H 2/T H 17 cells, which are crucial in mediating DEP-exacerbated allergic asthma exacerbations. [13] [14] [15] These double-producing effector T cells have been associated with severe asthma by numerous studies and have been shown to be refractory to steroid treatment. 16, 17 T H 17 cells isolated from patients with steroid-refractory asthma and treated with vitamin D have been shown to produce significantly decreased levels of IL-17A. 18 This study and others have shown that vitamin D has immunosuppressive effects on T H 17 cells. [18] [19] [20] Based on these data, we sought to establish whether vitamin D supplementation mitigates the effect of TRAP exposure on asthma development, asthma exacerbation, and/or airway inflammation and to determine the timing of vitamin D supplementation that confers the most beneficial health effect. We also examined the effect of vitamin D supplementation on the accumulation of effector T cells in the lungs.
METHODS
For a complete description of the materials and methods used in the murine and in vitro experiments, please see the Methods section in this article's Online Repository at www.jacionline.org.
Murine asthma model
Two different models of vitamin D supplementation were used: postnatal and prenatal supplementation. For postnatal supplementation, wild-type 3-week-old BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, Me), and mice were started on a normal chow diet. Mice were given either control water or water supplemented with 20,000 IU of cholecalciferol (Sigma, St Louis, Mo) ad libitum for 4 weeks before intratracheal challenge. After 4 weeks, mice underwent intratracheal challenges of saline, house dust mite (HDM; 10 mg comprising 3.3 mg of protein and 1.1 mg of Der p 1), DEPs (100 mg), or both and were challenged 3 times a week for 3 weeks, as previously described. 13 HDM extract (Dermatophagoides pteronyssinus) was purchased from Greer Laboratories (Lenoir, NC). DEPs were generated from a 4-cylinder Deutz diesel engine at the Environmental Protection Agency (Research Triangle Park, NC); detailed characterization of this compressor DEP has been described previously and compared with other sources of DEPs. 21 The mice were euthanized 24 hours after the last challenge. For the prenatal supplementation model, parents were started on a normal chow diet, and a subset of mice were given water supplemented with 20,000 IU of cholecalciferol (Sigma) ad libitum. Pups were continued on supplemented or control water consistent with their parents' diet and underwent the murine asthma model described above between 7 and 8 weeks of age.
All mice were housed in a specific pathogen-free environment in the animal facility at Cincinnati Children's Hospital Medical Center. All procedures were performed in accordance with the ethical guidelines in the Guide for the Care and Use of Laboratory Animals of the Institutional Animal Care and Use Committee approved by the Veterinary Services Department of the Cincinnati Children's Hospital Medical Center.
Vitamin D measurement
Plasma was obtained from mice retro-orbitally, and 25(OH)D levels were measured by using ELISA (DEIA 4458; Creative Diagnostics, Shirley, NY).
Airway responsiveness
Invasive measurements were made with the FlexiVent apparatus (SCIREQ, Montreal, Quebec, Canada) to measure airway responsiveness. Mice were anesthetized with ketamine, xylazine, and acepromazine (100, 20, and 10 mg/mL, respectively, mixed at a ratio of 4:1:1). Mouse tracheas were cannulated with a 19-gauge blunt needle, and mice were ventilated at 150 breaths/min and 3.0 cm H 2 O positive end-expiratory pressure. Two total lung capacity perturbations were then performed for airway recruitment before baseline measurement, and subsequent methacholine challenges were performed. Dynamic resistance was assessed after exposure to increasing concentrations of aerosolized methacholine (0, 3, 6.25, and 12.5 mg/mL). The average of the 3 highest dynamic resistance values with a coefficient of determination of 0.9 or greater (as determined by using flexiVent software) was used to determine the dose-response curve.
Bronchoalveolar lavage fluid collection and analysis
Bronchoalveolar lavage was performed by means of tracheal cannulation. Lungs were lavaged with 1 mL of MACS buffer (13 PBS, 0.5% BSA, and 2 mmol/L EDTA). The collected bronchoalveolar lavage fluid (BALF) was centrifuged, and total cell numbers were counted with a hemocytometer. Cells were spun onto slides and stained with the HEMA3 stain set (Fisher Scientific, Kalamazoo, Mich). After the slides were placed under cover slips and deidentified, 200 cells were counted, and total numbers of each cell type were calculated. rubber, and the strainer was washed with 5 mL of RPMI plus DNAse I media. Cells were centrifuged and resuspended in 1 mL of PBS plus 0.5% BSA plus 2 mmol/L EDTA before being counted on a hemocytometer.
Lung cells were ex vivo stimulated with phorbol 12-myristate 13-acetate plus ionomycin (0.05 and 0.5 mg/mL, respectively) for an hour before addition of Brefeldin-A (BioLegend, San Diego, Calif) for an additional 2½ hours to observe T H 2/T H 17 cytokine production. Approximately 500,000 lung cells were transferred to a 96-well plate with V-shaped wells on ice, centrifuged, and resuspended in PBS containing Fc Block (2.4G2 mAb). T cells were stained with combinations of CD4-fluorescein isothiocyanate, gd T-cell receptor-phycoerythrin/Cy7, CD25-Alexa Fluor 647, CD3-Alexa Fluor 700, and CD44-Pacific Blue (BioLegend). Cells were labeled with the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, according to the manufacturer's instructions (Invitrogen by Life Technologies, Carlsbad, Calif). Intracellular staining for IL-13-phycoerythrin, IL-17A-Alexa Fluor 647, IFN-g-peridinin-chlorophyll-protein complex 5.5, and forkhead box protein 3-peridinin-chlorophyll-protein complex 5.5 were conducted, according to the manufacturer's instructions (eBioscience, San Diego, Calif). Acquisition was done on a FACSCanto III (Becton Dickinson, Mountain View, Calif) and analyzed with FlowJo software (TreeStar, Ashland, Ore).
Statistical analysis
All statistical analyses were done with Prism software (GraphPad Software, La Jolla, Calif). Statistical significance was assessed by using 1-way ANOVA, followed by a Bonferroni posttest, except when mentioned otherwise in figure legends.
RESULTS

Vitamin D supplementation significantly attenuates development of airway hyperresponsiveness in mice coexposed to HDM plus DEPs
Three-week old BALB/c mice (juvenile age) were started on a normal chow diet with vitamin D-supplemented water or control water for 4 weeks to correct vitamin D levels to sufficient (>30 ng/mL) or deficient (<20 ng/mL) levels. 22 After 5 weeks, mice underwent 9 intratracheal challenges to saline, DEPs, HDM, or both HDM plus DEPs. The mice were continued on their respective diets throughout challenges to maintain vitamin D sufficiency or deficiency. Twenty-four hours after the last challenge, airway hyperresponsiveness (AHR) was measured. Consistent with previously published data by our group and others, mice coexposed to HDM plus DEPs have significantly increased AHR in comparison with mice exposed to only HDM. 13 Supplementation with vitamin D resulted in attenuated AHR in mice coexposed to HDM and DEPs (Fig 1, A and B) in comparison with coexposed vitamin D-deficient mice. Vitamin D supplementation had no/minimal effect on mice exposed to HDM alone, suggesting that vitamin D supplementation offers protection specifically in the context of DEP exposure. Vitamin D supplementation had no effect on total lung inflammation. There were no differences in the total lung cell, BALF cell, eosinophil, or neutrophil counts in the lungs between the groups (Fig 1, D-G) . There was a significant increase in lung neutrophilia and eosinophilia in HDM plus DEP-coexposed mice compared with mice exposed to HDM alone, as we have shown previously (Fig 1, F and G) . 13 
Vitamin D supplementation significantly decreases T H 2 and T H 2/T H 17 double-producing populations in the lungs
We have shown previously that T H 2, T H 17, and T H 2/T H 17 double-producing populations are increased in mice coexposed to HDM plus DEPs. 13 Lung cells were characterized by using flow cytometry to elucidate the effect of vitamin D supplementation on the presence of effector T cells in the lungs. Vitamin D supplementation resulted in significantly decreased numbers of T H 2 and T H 2/T H 17 double-producing populations in the lungs of mice coexposed to DEPs and allergen (Fig 2, A and C) . The frequency of regulatory T (Treg) cells in the lungs was not affected by vitamin D supplementation (Fig 2, D) . Also, vitamin D treatment did not significantly alter the mean fluorescence intensity of the positive T H 2 or T H 17 cells within the challenge groups (data not shown).
Prenatal vitamin D supplementation also significantly decreases development of AHR in mice exposed to HDM and coexposed to HDM plus DEPs
In the experiments above, vitamin D supplementation was initiated in early life at 3 weeks of age. We next examined whether in utero prenatal supplementation was equivalent to postnatal early-life supplementation or whether it could confer increased protection. BALB/c mice bred from parents receiving vitamin D-replete or control water underwent 9 intratracheal challenges at around 6 to 7 weeks of age (Fig 3, A) . The mice continued on their respective water source, and their serum vitamin D levels were greater than 30 and less than 20 ng/mL, respectively, at the start of the challenge. Vitamin D-supplemented mice coexposed to HDM plus DEPs developed attenuated AHR compared with vitamin D-deficient coexposed mice (Fig 3, B  and C) . A similar effect of vitamin D supplementation was observed in mice exposed to HDM alone, but the effect of vitamin D supplementation was most evident in the coexposed group (Fig 3, B and C) . Mice coexposed to HDM plus DEPs had increased BALF neutrophilia and eosinophilia compared with mice exposed to HDM alone, but vitamin D supplementation had no effect on total lung cell, BALF total cell, BALF eosinophil, or BALF neutrophil counts (Fig 3, D-G) .
Prenatal vitamin D supplementation significantly decreases T H 2 and T H 2/T H 17 double-producing populations in the lungs
We next examined whether prenatal vitamin D supplementation affected the pattern of lung effector T cells similar to what we observed with postnatal vitamin D supplementation. Mice coexposed to HDM plus DEPs had significantly increased T H 2, T H 17, and T H 2/T H 17 double-producing cells, as we previously published. 13 Allergen and DEP-coexposed mice prenatally and continuously supplemented with vitamin D water had significantly decreased T H 2 and T H 2/T H 17 double-producing populations present in the lung (Fig 4, A and C) compared with deficient mice. The frequency of Treg cells in the lungs was not different between the subgroups (Fig 4, D) .
Prenatal vitamin D supplementation is superior at attenuating the development of AHR in mice coexposed to HDM plus DEPs Although both prenatal and postnatal supplementation were effective in preventing the development of AHR, we next directly compared the 2 treatments to determine whether one conferred increased health benefit. Vitamin D levels were similar at the start of both the prenatal and postnatal experimental protocols (Fig 5, A) . Prenatal supplementation resulted in a 75.5% decrease in observed AHR between supplemented and deficient mice, whereas postnatal supplementation resulted in a decrease of 66.5% (Fig 5, B) . Thus, although both prenatal and postnatal supplementation were effective, prenatal care conferred increased health benefit.
Vitamin D does not confer protection against DEP-induced asthma exacerbation once asthma is established
BALB/c mice were exposed to allergen or allergen plus DEPs to induce asthma, as previously published, 13 to determine whether vitamin D supplementation would attenuate AHR once asthma was already established. Once asthma was established, the mice A, Protocol: BALB/c mice were started on vitamin D supplementation or control water for 4 weeks and then exposed intratracheally (i.t.) to saline (S), DEPs (100 mg; D), and/or HDM (10 mg; H) 3 times a week over 3 weeks. B, Airway resistance was measured 24 hours after the last challenge (n 5 4-12 mice per group). C, Resistance after exposure to 12.5 mg/mL methacholine. D, Total lung cell counts. E, BALF cell counts. F, BALF eosinophil counts. G, BALF neutrophil counts. ****P < .0001, 2-way ANOVA.
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were started on vitamin D supplementation to achieve sufficient levels of greater than 30 ng/mL (see Fig E1, A, in this article's Online Repository at www.jacionline.org). There were no significant differences observed in AHR or airway inflammation between vitamin D-supplemented and deficient mice in either HDM-exposed or HDM plus DEP-coexposed mice (see Fig E1, B) . Thus, although vitamin D supplementation prevented DEP-induced allergic asthma development, it had no benefit once asthma was established.
DISCUSSION
Recent epidemiologic studies have suggested that vitamin D deficiency specifically makes children susceptible to the effects of TRAP exposure. Our results offer the first evidence that this is the case. Specifically, our data demonstrate that coexposure to TRAP and allergen in the context of vitamin D deficiency results in increased asthma development and asthma severity. Furthermore, prenatal or postnatal supplementation with vitamin D confers protection against this negative health effect of TRAP exposure. 1 T cells producing IL-13 (Fig 2, A) , IL-17A (Fig 2, B) , or IL-13/IL-17A (Fig 2, C) or staining for CD25 1 Foxp3 1 Treg cells (Fig 2, D) . E, Representative dot plots (n 5 4-12 mice per group). *P < .05 and ***P < .001, 1-way ANOVA with the Bonferroni multiple comparison test (n 5 4-12 mice per group). These findings have a tremendous public health effect because in large cities in North America, up to 45% of the population resides in zones that are most affected by TRAP and more than 30% of schools are located in areas of high TRAP exposure. 12 Furthermore, although truck engines are being designed to decrease particle emissions, air quality and engine exhaust control policies implemented in 2005-2010 have not produced significant changes in traffic air pollution levels. 23 Given the suggestive evidence of protective effects of vitamin D from observational studies, numerous clinical trials have been conducted to examine the effect of vitamin D supplementation on asthma outcomes. Tachimoto et al 24 found improved asthma control in asthmatic children supplemented with 800 IU of vitamin D3 for 2 months. However, other studies show a lack of or even adverse effects of vitamin D in patients with established asthma. [25] [26] [27] [28] This is not surprising given our findings that vitamin D confers no health benefit once asthma is established. Indeed, the recently published Vitamin D and Asthma trial in adults found no significant differences in treatment failure and time to first exacerbation. 29 Recent studies have also examined the potential for prenatal vitamin D supplementation as a preventive strategy. The Vitamin D Antenatal Asthma Reduction Trial was designed to determine whether prenatal vitamin D (cholecalciferol) supplementation 
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1 T cells producing IL-13 (Fig 4, A) , IL-17A (Fig 4, B) , or IL-13/L-17A (Fig 4, C) or staining for CD25 1 Foxp3 1 Treg cells (Fig 4, D) . E, Representative dot plots. *P < .05 and **P < .01, 1-way ANOVA with the Bonferroni multiple comparison test (n 5 4-8 mice per group).
could prevent asthma or recurrent wheeze in early childhood. 30 The incidence of asthma and recurrent wheezing in their children at age 3 years was decreased by 6.1% in the group supplemented with 4400 IU/d of vitamin D; however, this did not meet statistical significance. Unfortunately, the groups were not stratified by TRAP exposure, and as the authors note, the study might have been underpowered. A recent meta-analysis was published to examine the current literature and observe the associations between 25(OH)D levels in cord or maternal blood and risk of childhood asthma, wheeze, and respiratory tract infection. 31 Feng et al 31 found that increased in utero exposure to 25(OH)D decreases the risk of persistent wheeze and asthma on analysis of 16 birth cohorts. Similarly, another meta-analysis revealed that prenatal intake of vitamin D might protect against the development of recurrent wheeze in children. 32 Although these epidemiologic studies are consistent with our findings, our data suggest that the observed health benefit of vitamin D supplementation is likely to be most evident among children and mothers exposed to high levels of TRAP. Indeed, several recent reviews and editorials have concluded that additional studies are needed to determine whether vitamin D would benefit patients with specific exposures or asthma disease endotypes.
Ethical issues also arise when participants remain vitamin deficient to serve as control subjects for these studies. 33 Our data strongly support that children and pregnant mothers exposed to high levels of TRAP would benefit most from vitamin D intervention. This lack of attention to TRAP exposure might in part explain the disparate findings.
We found that both prenatal and early-life continuous vitamin D supplementation attenuated the development of AHR in mice. Prenatal supplementation offered the most protection, but additional studies are necessary to determine whether the observed differences between prenatal and postnatal supplementation are clinically relevant. Future studies will also need to address how long the protection lasts after normalization of vitamin D status and whether supplementation must be continued to protect against future persistent DEP challenges. Our data suggest that the optimal window for vitamin D's protective effects is in early life, perhaps before allergen sensitization. To test this, we challenged vitamin D-sufficient and deficient mice to saline, HDM, or HDM plus DEPs once a week for 3 weeks to determine whether vitamin D effects sensitization (see Fig E2, A, in this article's Online Repository at www.jacionline.org). There were no significant differences in levels of the HDM-specific antibodies IgG 1 and IgE (see Fig E2, B and C) .
Lungs, spleens, and mediastinal lymph nodes were then ex vivo stimulated with HDM for 6 days, and culture supernatants were analyzed for IL-5 and IL-13 production. No significant differences were noted in spleen or lymph node cultures (data not shown). Thus vitamin D does not have a major effect on allergen sensitization in this model. It remains possible that vitamin D has an effect on sensitization at lower doses. Interestingly, lung cells from mice challenged with HDM plus DEPs secreted significantly more IL-13 upon ex vivo stimulation, and this was significantly decreased in mice that were supplemented with vitamin D (see Fig E2, D) . This further suggests that the protective effects of vitamin D are mediated, at least in part, by decreased numbers of effector T H 2 and T H 2/T H 17 cells. Although vitamin D was able to prevent asthma development, once asthma was established, there was no significant benefit of vitamin D supplementation on future asthma exacerbations in either HDM-or HDM plus DEP-challenged mice (see Fig E1, B) . These results might explain why vitamin D treatment has not been successful in treatment studies. [25] [26] [27] [28] In children TRAP exposure is associated with increased serum IL-17A levels and increased asthma severity. 13 Consistent with this, in mice DEP exposure results in more severe allergic asthma and the accumulation and persistence of allergen-specific T H 2/T H 17 cells in the lungs. 34 These cells rapidly produce T H 2 and T H 17 cytokines on re-exposure to antigen. The persistence of these resident memory effector cells in the lungs after TRAP exposure might be responsible, in part, for the asthma-promoting effects of TRAP exposure.
Given recent reports demonstrating that vitamin D downregulates IL-17 production, it is possible that vitamin D can have a direct effect on T H 17 cells. One study found that vitamin D deficiency is associated with enhanced production of IL-17A in patients with asthma and that IL-17A production is inhibited by vitamin D treatment independent of steroids. 18 Another study found that vitamin D reduces the differentiation -15) . B, Difference in AHR between vitamin D-supplemented and deficient coexposed mice was measured. The average AHR response of deficient coexposed mice was normalized to 100 and compared with that of supplemented mice. *P < .05, t test.
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 and expansion of T H 17 cells in asthmatic children. 19 Here we observed that T H 2 and T H 2/T H 17 cells were uniquely affected by vitamin D supplementation. In contrast, eosinophil, neutrophil, and Treg cell numbers were unaffected. T H 2/T H 17 double-producing cells have been shown to be more pathogenic in their ability to secrete cytokines and exacerbate allergic asthma. 35 They have also been associated with severe steroid-resistant asthma. 16 In summary, our data reveal that in the context of vitamin D deficiency, these pathogenic effector cells, which promote the development and persistence of asthma, accumulate in the lungs. Early supplementation with vitamin D prevents accumulation of these cells and prevents asthma development. These data have obvious clinical implications and support the need for a trial to examine the efficacy of vitamin D supplementation in preventing asthma development in children exposed to high levels of TRAP.
METHODS
Murine models
To assess vitamin D as a treatment, BALB/c mice were challenged intratracheally with saline, HDM, and HDM plus DEPs 3 times a week for 3 weeks to establish airway disease. Then a subset of mice was given either control water or water supplemented with 20,000 IU of cholecalciferol (Sigma) ad libitum for 6 weeks (to attain sufficient vitamin D levels) before a single HDM (10 mg) intratracheal challenge. For the vitamin D sensitization experiment, mice were challenged once a week for 3 weeks with saline, HDM, or HDM plus DEPs. Six days after the last intratracheal challenge, lungs, spleens, and mediastinal lymph nodes were plated at 100,000 cells per well in triplicate and ex vivo stimulated with HDM (25 mg) for 6 days before supernatant collection.
ELISA
Plasma HDM-specific IgE and IgG 1 levels and supernatant IL-13 levels (free and IL-13 receptor a2 bound) were assessed, as previously described.
E1
IL-5 levels were determined by using the IL-5 ELISA kit (BioLegend).
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 1 FIG E1. Vitamin D restoration after established asthma had no effect on AHR on rechallenge with HDM. A, Protocol: BALB/c mice were exposed to saline, HDM, or HDM plus DEPs. A subset of mice were started on vitamin D-supplemented water for 6 weeks to restore vitamin D levels. The mice then received a single challenge of HDM (10 mg). i.t., Intratracheal. B, Airway responsiveness was measured 48 hours after the last challenge (n 5 4-8 mice per group). deficient BALB/c mice were exposed to saline (S), HDM (H), or HDM plus DEPs (H1D) once a week for 3 weeks. Mice were killed 6 days later, and lung cells were ex vivo stimulated with HDM for 6 days before culture supernatant collection. i.t., Intratracheal. B, HDM-specific IgG 1 levels. C, HDM-specific IgE levels. D, IL-13 OD levels. E, IL-5 OD levels. ***P < .001, 1-way ANOVA with the Bonferroni multiple comparison test (n 5 4-9 mice per group).
